71results about How to "Reduce restenosis rate" patented technology

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

One aspect of the invention relates to a stent, a surface of which is coated with an amphiphilic copolymer that includes both hydrophobic and hydrophilic polymer chains. An amphiphilic copolymer coating according to the invention can serve as a carrier for a very broad range of drugs. The release rates of the drugs can be controlled, for example, through the length of the polymer chains, through their ratio, or through the degree of crosslinking.

As a treatment for angiostenosis, angioplasty (PTA or PTCA) of expanding a small-sized balloon in a vessel has been commonly conducted. However, this treatment easily causes repeated stenosis (restenosis) after the treatment. Placement of a stent in a vessel is also effective in decreasing restenosis, but this treatment may also cause restenosis. The present invention provides a stent containing a poly (lactide-co-glycolide) or both a poly (lactide-co-glycolide) and an immunosuppressive agent in at least a portion of a surface of the stent, and further containing a material nondegradable in vivo.

The invention concerns an endovascular implant for the application of an active substance into the media 22 of a blood vessel and two processes for the production thereof. A base body 42 of the implant has at least in portion-wise manner at a surface 40 which is towards the blood vessel, a plurality of microdevices 10 for injection of the active substance. Each microdevice 10 includes on the one hand at least one microcannula 38 which is raised out of the surface 40 of the implant to such an extent that, when the implant bears against a wall 12 of the blood vessel in surface contact, the microcannula penetrates into the media 22 of the blood vessel, and on the other hand at least one active substance deposit 36 which is in communication with at least one microcannula 38.

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

The invention relates to a medical apparatus, in particular to an anticoagulant stainless steel coronary support which is made from a high-nitrogen nickel-free austenitic stainless steel material with good blood compatibility. The support is of tubular structure with a mesh surface which is formed by orderly arranging a unit figure on the side surface of a tube along the circumference and axial direction, the primary supporting function is provided by U-shaped corrugated mesh wires extending along the axial direction, the corrugated mesh wires are connected into a whole body by soft mesh wires arranged at intervals, and the diameter of the mesh wire (width or thickness) is 40-100mum; and the surface of the support is passivated and coated with a medication. The anticoagulant stainless steel support has the advantages of good mechanical properties, good flexibility and good anticoagulant property, and can be used as a support for cardiovascular and cerebrovascular systems or a support for other cavity bodies.

The present invention relates to a hole for the medicine elution apparatus and a polymer carrying medicine releasing structure and the preparing method thereof. The invention includes an apparatus body which is arranged with large numbers of holes, the large number of holes are nano-scale holes with single dimension or double dimensions of a plurality of dimensions, namely n nano-scale holes with equal dimension arrangement or two or more asymmetrical dimension arrangement with the statistical average value including the pore diameter of pore depth, the holes are structure of medicine-carrying groove or pore, and the apparatus body includes or not includes an outermost membrane layer, the mixture of medicine and polymer exists in the hole and the mixture adheres to the surface of the apparatus body; the carrier carrying the medicine is no longer the simple hole or polymer, the holes and a few polymers commonly supports the active medicine and does controlled-releasing to the medicine, facilitates that the medicine has a strong adsorbability and a good controlled-releasing effect, as the content of the polymer is small the invention has the advantages of reducing the risk formed by the long-period thrombus and safer using and better treating effect.

The invention provides a method for manufacturing artificial blood vessels with double-layered structures and application of the artificial blood vessels, and discloses a method for manufacturing artificial blood vessels with double-layered structures and a method for applying the artificial blood vessels. The method for manufacturing the artificial blood vessels with the double-layered structures includes a first step, manufacturing inner oriented micron fiber layers of the artificial blood vessels with the double-layered structures; a second step, manufacturing outer random nano-fiber layers of the artificial blood vessels with the double-layered structures. The method for applying the artificial blood vessels includes transplanting the double-layered artificial blood vessels in situ so as to replace lesion blood vessels. The methods have the advantages that vascular smooth muscle cells can be induced in vivo by oriented micron fibers of the inner layers of the artificial blood vessels to be regenerated just like oriented structures of natural blood vessels, sufficient suture strength and mechanical properties of the blood vessels can be guaranteed by the outer random nano-fiber layers, and accordingly the artificial blood vessels can be used for repairing and replacing the lesion natural blood vessels; the double-layered artificial blood vessels have excellent application prospects in the field of medical clinical vascular transplantation.

The invention discloses a medical degradable Zn-Cu-X alloy material and a preparation method thereof. The alloy material includes the following components in percentage by weight: 1-10% of Cu, 0-4% of X and the balance Zn, wherein the element X is one of Mg, Ca, Sr, Si, Fe, Mn, Ag, Y, Nd, Gd, Er, Ho and Dy or is a mixture of more of Mg, Ca, Sr, Si, Fe, Mn, Ag, Y, Nd, Gd, Er, Ho and Dy. The invention further relates to the preparation method of the alloy material. The alloy material provided by the invention is a multi-element degradable Zn-based alloy material composed of the human nutrient elements Zn, Cu and X, which completely have biosecurity, has favorable biocompatibility, excellent mechanical properties and an adjustable and controllable corrosion rate, and has a favorable application prospect in the field of medical degradable inner implantation material.

The invention relates to a stent having a coating or cavity filling comprising or containing an organic Au complex.

The invention discloses a medicine coating balloon. The medicine coating balloon comprises a balloon body and a medicine coating covering the surface of the balloon body, wherein the medicine coatingis formed by spraying a medicine spraying solution to the surface of the balloon body; and the medicine spraying solution is obtained by dissolving medicine, a fat-soluble excipient and a hydrophilicexcipient in a solvent. The invention further discloses a preparation method of the medicine coating balloon and a medicine coating balloon dilatation catheter. According to the medicine coating balloon, the firmness of the medicine coating is higher, the granularity of the medicine is small, the medicine loss can be greatly reduced in the medicine balloon crossing and dilatation process, the tissue absorption rate is high, and the medicine utilization rate is increased.

The invention relates to a medicine coated balloon and a preparation method thereof. The coating is prepared from the following raw materials in parts by weight: 5-9 parts of a medicine, 1-5 parts of excipient and 1-15 parts of a solvent, wherein the medicine is at least one of taxanes and macrolides; the excipient is at least one of iopromide, polyvinylpyrrolidone, polysorbate and polyethylene glycol; and the solvent is at least one of water, methanol, ethanol, acetone, isopropanol, acetonitrile, ethyl acetate and methyl formate. According to the method, by optimizing the composition of coating raw materials, the proportion of raw materials and the process parameter in the coating preparation method, the coating cannot be easily separated before reaching the target site and can quickly release the medicine when reaching the target site, the target tissue can be promoted to absorb the medicine in the coating, the medicine duration in the target tissue can be improved, and the vessel restenosis rate after interventional therapy can be reduced.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and / or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and / or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

The invention relates to a sterilization treatment method for a biological coating medical device, wherein a biological activity protective coating is coated outside a biological coating on the surface of the medical device, is subjected to freeze-drying treatment and is sterilized by the radiation of Co60-gamma rays. The germicidal treatment method provided by the invention adopts the biologicalactivity protective coating, and can avoid the radiation of Co60-gamma rays from damaging biological activity compositions while ensuring the sterilization effect; moreover, the method also has the advantages of simple process, safe use and high industrial practicability.

The invention relates to a nanometer medicinal elution apparatus in microcellular structure for storing and releasing multiple medicines and a preparation method thereof. The multiple medicines in the invention are selected from medicine therapeutic agents, carrier therapeutic genes and bioactive substances, wherein one or two of the medicine therapeutic agents is / are taxol and / or probucol. The preparation method of the medicinal elution apparatus in the invention mainly comprises the followings: 1) nanometer holes are prepared on the surface of the apparatus body; 2) multiple medicines are coated in the nanometer holes and on the surface of the apparatus body. The apparatus body in the invention does not contain polymers, thereby reducing the risk of long-term thrombus possibly caused by polymers; the nanometer holes on the surface of the apparatus body do not have any influence for mechanical property of the body, thereby being capable of efficiently controlling the releasing rate of medicines and obviously reducing the restenosis rate after surgical operations. The invention can be applied to various medicinal elution implanting apparatuses, particularly having good effects for curing vascular lesion and preventing blood vessel restenosis in vascular stents.

The invention discloses a reticulated endovascular stent which comprises a plurality of supporting unit rings and connecting bars, wherein the supporting unit rings consist of a plurality of wave-shaped bars with wave-shaped structures; the connecting bars are connected to the adjacent supporting unit rings to form the cylindrical reticulated endovascular stent, the axial length of each supporting unit ring is less than 1.36mm, and the optimal range is between 0.65mm and 1.03mm; the distance between every two adjacent supporting unit rings is less than 0.5mm, and the optimal range is between 0.1mm and 0.44mm; the connecting bars positioned among different supporting unit rings are axially crossly arranged; the connecting bars connected with the supporting unit rings at two axial ends of the stent are set to be n-shaped connecting bars, and other connecting bars are blocky entity bars and / or short curved bars; and wave crests and / or troughs of the curved bars are provided with strengthening rings strengthening the supporting force. The stent has smaller mesh, can effectively lower the postoperative restenosis rate, and improves the medical treatment effect. The reticulated endovascular stent is suitable to the interventional technique, and is especially suitable to the percutaneous coronary intervention.

The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.

The invention relates to a medical product for interventional therapy, in particular to a novel intravascular coated stent which comprises a stent body and a coat. The coat comprises a polymer bottom layer formed by coating on the surface of the stent body and multilayer silk peptide layers and chitosan layers which are formed by coating on the surface of the polymer bottom layer, wherein the silk peptide layers and the chitosan layers are arranged alternately. A stent coat is prepared by a method of layer upon layer electrostatic self-assembly, has better compatibility with blood, and can reduce late restenosis rate of stent post-operative heart.

The invention discloses application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis. Experimental research finds that salvianolic acid A can restrain proliferation of umbilical cord artery blood vessel smooth muscle cells of a person and reduce the tunica intima thickening rate and the blood vessel lumen restenosis rate of a tunica intima thickening animal model after balloon injury, has the remarkable effects of resisting tunica intima thickening and post-angioplasty restenosis and / or in-stent restenosis, can be used for preparing the medicine for restraining tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis and is particularly used for preparing medicine for preventing post-percutaneous coronary angioplasty restenosis and in-stent restenosis or used for preparing a drug eluting stent. In this way, efficient, safe and economical prevention and treatment medicine and an efficient, safe and economical solution are provided for prevention and treatment of post-angioplasty, particularly post-percutaneous coronary angioplasty restenosis and in-stent restenosis.

The invention relates to a preparation method for a medical product for interventional therapy, in particular to a preparation method for a novel intravascular coated stent. The preparation method comprises the following steps: coating on the surface of a stent body through a method of electrostatic self-assembly layer upon layer to form a polymer bottom layer, and alternately coating on the surface of the polymer bottom layer to form multilayer silk peptide layers and chitosan layers. A stent coat obtained by the preparation method has better compatibility with blood, and can reduce late restenosis rate of post-operative heart.

It is an object of the present invention to overcome certain disadvantages of stents, such as drug eluting stents. In particular, it is an object to provide a stent with improved re-endothelialization ability and / or simultaneous reduced rate of restenosis and / or minimal or no inflammatory potential.

The invention discloses a degradable vascular stent structure with a negative Poisson ratio to make up defects of design of degradable vascular stents in the prior art and belongs to the field of medical equipment. The vascular stent structure is formed by arranging concave hexagonal base structure units in the annular and axial directions of a stent and is made of a degradable material. The vascular stent structure is designed on the specificity of the degradable material and has a negative Poisson ratio effect. A degradable vascular stent with the structure can be matched with the negative Poisson ratio effect of tunica intima tissue after being implanted into blood vessels, so that injury caused by the stent to vascular tissue and the probability of in-stent restenosis are reduced, thestent can be completely degraded in vivo finally, and degradation products of the stent are absorbed and metabolized by the human body.

The invention provides a high-nitrogen austenitic stainless steel material for a vascular stent, which comprises the following chemical components in percentage by weight: 16-20% of Cr, 12-20% of Mn, 1-3% of Mo, 0.5-2% of Cu, no more than 0.05% of Ni, 0.7-1.2% of N, 0.5-8% of W, 0.05-0.5% of RE, no more than 0.08% of C, 0.3-4% of Si, no more than 0.010% of S, no more than 0.02% of P and the balance of Fe, wherein RE is a rare-earth element. The high-nitrogen stainless steel provided by the invention is mainly used for vascular stent processing; the elements of copper, nitrogen and rare earth are added to increase the blood compatibility of the stainless steel; and the tungsten alloy is added to increase the density of the stainless steel. The stainless steel has excellent visibility under X rays, contains no potential toxic element nickel, can be used in the aspects of surgical implants, medical appliances, food and catering appliances, jewelry and other stainless steel products which are always in contact with a human body, and can also be used in the fields of chemical engineering, environment protection and the like.

Method and apparatus for treatment and post-treatment of the stenosed region of an artery after reduction of the region by angioplasty or other means by applying a radioactive dose to said reduced region of the artery by positioning a radioactive dose to the reduced region is disclosed.

The invention relates to a drug-eluting stent carrying therapeutically effective dose of short-chain ceramide. The stent comprises a stent body. The stent is characterized in that: the stent body carries therapeutically effective dose of short-chain ceramide. The ceramide medicine carried by the stent body provided by the invention can directly contact tumor tissues. When the stent is used in combination with total body paclitaxel anti-microtubule cytotoxic drug chemotherapy, tumor growth can be substantially inhibited, tumor cell apoptosis can be promoted, and lumen restenosis rate can be reduced. The stent body is produced from a high-molecular polymer material. The stent has good histocompatibility. When mechanical supporting with a certain period of time is accomplished, the stent is automatically degraded. The degradation product brings no toxic or side-effect to tissues, and is not necessary to be taken out by a secondary operation. A degradable polymer auxiliary agent can be added into the stent body for improving the toughness, plasticity and workability of the stent body. Degradation speed and medicine releasing speed of the stent can be regulated according to clinical requirements, such that the stent can satisfy clinical requirements, and controllability of the stent can be improved.

Methods for treating and / or preventing restenosis in a subject by local administration to the subject of a composition that includes keratinocytes is disclosed. Administration is preferably by way of a catheter having an inflatable balloon, such as a double or dumbbell-shaped balloon.